CD8A and neoplasm: B16 melanoma cells engineered to overexpress IL-36γ displayed reduced tumour growth and improved prognosis, with IL-36γ promoting the activation and proliferation of CD8+ cells and NK cells [9] compared to B16 control-injected mice.